Interestingly, in line with the last observation and with the reported decreased T cell functions in severe COVID-19 [26], the CCL5 molecule is elevated from the early stages post-infection in the plasma of COVID-19 patients with mild but not severe disease [97], promoting its candidacy among the potential prognostic markers useful to predict SARS-CoV-2 infection outcomes. The gene discussed is CCL5; the disease is COVID-19.